Biotechnician - Considering that advancement of the pipeline has been delayed for 3-4 years, it's understandable that some would question whether this year's promises will also fall by the wayside. From the earnings release dated December 29, 2014, Upcoming Milestones section:
>Initiate double-blinded, randomized, placebo-controlled Phase 2 human trial of ANAVEX 2-73 in non-disclosed indication.
>In addition to ongoing Phase 2a trial currently in PART B, start larger, double-blinded, randomized, placebo-controlled Phase 2/3 trial of ANAVEX 2-73 for Alzheimer’s disease.
And this paragraph from the Recent Corporate Highlights section:
On November 18, 2015, Anavex announced that it is moving forward with the development program for ANAVEX 2-73 based on formal interaction and guidance from the FDA, which confirmed the Company’s strategy to advance ANAVEX 2-73 for the treatment of Alzheimer’s disease in a larger double-blinded, randomized, placebo-controlled Phase 2/3 trial.
But wait, there's more. These four bullets from the December 29, 2014, earnings release:
>First patient dosed for Phase 2a study for ANAVEX 2-73 and ANAVEX PLUS (REALLY? A2-73 AND ANAVEX PLUS?? WHAT HAPPENED TO THIS TRIAL???)
>Report topline data from Phase 2a study in Q3 2015
>Preparation for Phase 3 study in 2015
>In-licensing to complement current pipeline – ongoing
So to sum up, TGD has a long history of over-promising and under-delivering.
News 
Market Data 
Discover 
AI
